OptiBiotix Health’s (OPTI) fully-owned subsidiary ProBiotix Health has signed a non-exclusive license agreement with Tenshindo to use Lactobacillus plantarum, or LPLDL®, in cardiovascular food supplements in Japan.
LPLDL® is set to be the active ingredient in Tenshindo’s cardiovascular health product.
The Japanese partnership opens up a new market for the life sciences company as it continues to focus on compounds designed to tackle obesity, cardiovascular disease and diabetes.
It also represents the first end product application deal that has emerged from ProBiotix’s agreement with Japanese distributor EIWA Trading Corporation, signed earlier this year, to distribute LPLDL® in the country.
Dr. Luis Gosalbez, Business Development Director of OptiBiotix, commented: "We are pleased to announce this deal with Tenshindo, which will mean our first LPLDL® finished product placement on the Japanese market.
Obtaining an authorised cardiovascular health claim for LPLDL® from Japanese authorities will not only be highly advantageous from the commercial point of view, but also an important endorsement for ProBiotix's science. Tenshindo, with over 30 years of experience in this market, are an excellent commercial and regulatory partner to make the most of this opportunity."
For more news and updates on OptiBiotix Health: